Efficacy and tolerability of fluvastatin extended-release delivery system: A pooled analysis

Clinical Therapeutics

Volumn 23, Issue 2, 2001, Pages 177-192

  Battantyne, Christie M ^a   Pazzucconi, Franco ^b   Pintó, Xavier ^c   Reckless, John P ^d   Stein, Evan ^e   McKenney, James ^f   Bortotini, Michele ^g   Chiang, Yann Tong ^g  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d ROYAL UNITED HOSPITAL   (United Kingdom)

^e Pharmaceutical Product Development   (United States)

^f National Clinical Research Inc   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Extended release formulation; Fluvastatin; HDL cholesterol; Hypercholesterolemia; LDL cholesterol; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG TOLERABILITY; EXTENDED RELEASE FORMULATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; IMMEDIATE RELEASE FORMULATION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE FORMULATION;

EID: 0035082566     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80001-1     Document Type: Article

References (30)

1. Mortality by cause for eight regions of the world: Global Bureau of Disease Study
2. Preventing coronary artery disease by lowering cholesterol levels
3. Systemic review on the risk and benefit of different cholesterol-lowering interventions
4. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
9. Range of serum cholesterol values in the population developing coronary artery disease
10. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
11. Fluvastatin: A review of its use in lipid disorders
12. The effect of fluvastatin on coronary events in patients with symptomatic coronary artery disease during one year of treatment
13. A randomized placebo-controlled trial of fluvastatin for the prevention of restenosis after successful coronary balloon angioplasty: Final results of the Fluvastatin Angiographic Restenosis (FLARE) trial
14. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
15. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: A randomized trial
16. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
17. A review of clinical trials comparing HMG-CoA reductase inhibitors
18. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: A reappraisal
19. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
20. Pharmacokinetics of fluvastatin and specific drug interactions
21. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers
22. Safety, tolerability and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia
23. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data
24. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins
25. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia
26. Comparison of statins in hypertriglyceridemia
27. Fluvastatin: A review of its pharmacology and use in the management of hypercholesterolaemia